Dr. Elizabeth Smyth on Upper GI Cancer Innovations, Trials, Guidelines and Collaboration
In this episode of OncoInfluencers, host Ravi Karra speaks with Dr. Elizabeth Smyth, a leading consultant medical oncologist specializing in upper GI cancers at Oxford NHS Foundation Trust. Dr. Smyth shares her remarkable journey from Ireland to leading academic and clinical roles in oncology across the UK, including her work with EORTC, ESMO, and as a founding member of the UK and Ireland Oesophageal Cancer Group. The conversation explores innovations in upper GI cancer care — from immune checkpoint inhibitors, ADCs, and T-cell engagers to perioperative treatments and emerging biomarkers. Dr. Smyth also reflects on challenges in adopting new therapies, balancing financial and clinical toxicity, and the evolving role of CAR T-cell therapies in solid tumors.
Topics discussed:
- Dr. Smyth’s personal and professional background
- Advances in immune checkpoint inhibitors and targeted therapies
- Challenges with CAR T-cell therapies in solid tumors
- The future of perioperative treatment strategies
- The role of international academic collaboration (EORTC, ESMO)
- The importance of holistic, patient-centered care
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023